CAJ | 학술논문

目的了解2剂赛尼哌治疗方案能够在1个月内完全阻断白细胞介素2受体(IL-2R),减少T细胞增殖,停用赛尼哌后是否还存在延续作用,除了IL-2R被阻断这个途径外是否还存在其他途径来调节免疫.方法对15例常规免疫抑制三联疗法(对照组)以及15例使用2剂赛尼哌诱导治疗(诱导组)的同种异体肾移植患者均随访6个月,每个患者均在术前2 h,术后1个月,术后3个月以及术后6个月检查IL-2,IL-10,STATS以及CD40L水平.结果术前2 h、术后1个月、3个月以及6个月的IL-2,STATS水平,诱导组和对照组间差异无统计学意义.IL-10水平在术后3个月时诱导组(59.4±7.7)ng/L明显高于对照组(36.8±8.4)ng/L.CD40L水平在术后1个月时诱导组(10.6±3.6)明显低于对照组(35.6±8.4).结论赛尼哌能够在术后1个月时通过抑制CD40L水平来减少B细胞介导的体液免疫反应的发生.
목적 료해2제새니고치료방안능구재1개월내완전조단백세포개소2수체(IL-2R),감소T세포증식,정용새니고후시부환존재연속작용,제료IL-2R피조단저개도경외시부환존재기타도경래조절면역.방법 대15례상규면역억제삼련요법(대조조)이급15례사용2제새니고유도치료(유도조)적동충이체신이식환자균수방6개월,매개환자균재술전2 h,술후1개월,술후3개월이급술후6개월검사IL-2,IL-10,STATS이급CD40L수평.결과 술전2 h、술후1개월、3개월이급6개월적IL-2,STATS수평,유도조화대조조간차이무통계학의의.IL-10수평재술후3개월시유도조(59.4±7.7)ng/L명현고우대조조(36.8±8.4)ng/L.CD40L수평재술후1개월시유도조(10.6±3.6)명현저우대조조(35.6±8.4).결론 새니고능구재술후1개월시통과억제CD40L수평래감소B세포개도적체액면역반응적발생.
Objective To determine whether there was any lingering effect after discontinuing Zenapax in renal transplantation and investigate there was any alternative immunity-regulating pathway of Zenapax other than IL-2/IL-2R. Methods Thirty patients of renal transplantation were divided into 2 groups. One group of 15 received 2 dosages of induction therapy of Zenapax and another 15 regular immunosuppressive therapy. IL-2, IL-10, STAT5 and CD40L were tested followed up at 2 hours pre-transplantation, 1, 3 and 6 months post-transplantation. Results The levels of IL-2 and STAT had no difference between the induction group and the control group. The level of IL-10 of induction group(59.4±7.7)ng/L was obviously higher than control group (36.8±8.4) ng/L at 3 months post-transplantation. CD40L level of induction group(10.6±3.6) was lower than control group(35.6±8.4) at 1 month post-transplantation. Conclusion Zenapax can reduce B-cell-mediated humoral immunity at 1 month post-transplantation through CD40L pathway.